Clinical and economic outcomes associated with the use of fluticasone propionate 250 mcg and salmeterol 50 mcg combination versus tiotropium bromide 18 mcg as initial maintenance treatment for chronic obstructive pulmonary disease in managed care

References

• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Washington, DC: GICOLD; 2016. http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/
   Google Scholar
• World Health Organization (WHO). Chronic obstructive pulmonary disease (COPD). Fact sheet No. 315. Washington, DC: WHO; 2015. http://www.who.int/mediacentre/factsheets/fs315/en/
   Google Scholar
• Aaron SD, Donaldson GC, Whitmore GA, et al. Time course and pattern of COPD exacerbation onset. Thorax 2012;67:238-43
   PubMed Web of Science ®Google Scholar
• Bhowmik A, Seemungal TA, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114-20
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52
   PubMed Web of Science ®Google Scholar
• Wilkinson TM, Hurst JR, Perera WR, et al. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest 2006;129:317-24
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22
   PubMed Web of Science ®Google Scholar
• Spencer S, Calverley PM, Burge PS, et al. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004;23:698-702
   PubMed Web of Science ®Google Scholar
• Andersson F, Borg S, Jansson SA, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002;96:700-8
   PubMed Web of Science ®Google Scholar
• Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925-31
   PubMed Web of Science ®Google Scholar
• Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006;27:397-412
   PubMed Web of Science ®Google Scholar
• Chapman KR, Mannino DM, Soriano JB, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006;27:188-207
   PubMed Web of Science ®Google Scholar
• Minino AM, Murphy SL, Xu J, et al. Deaths: final data for 2008. Natl Vital Stat Rep 2011;59:1-126
   PubMedGoogle Scholar
• Mannino DM, Kiriz VA. Changing the burden of COPD mortality. Int J Chron Obstruct Pulmon Dis 2006;1:219-33
   PubMedGoogle Scholar
• US Department of Health and Human Services. Chronic obstructive pulmonary disease. Washington, DC: USDHHS. Data fact sheet; 2003. https://www.cdc.gov/copd/index.html
   Google Scholar
• American Lung Association. COPD 2013 prevalence and mortality by State and sex. Washington, DC: ALA; 2013. http://www.lung.org/assets/documents/research/copd-2013-prevalence-and.pdf
   Google Scholar
• NIH/NHLBI. Morbidity & Mortality: 2012 Chart book on cardiovascular, lung, and blood diseases. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 2012. https://www.nhlbi.nih.gov/files/docs/research/2012_ChartBook_508.pdf
   Google Scholar
• Ford ES, Croft JB, Mannino DM, et al. COPD surveillance—United States, 1999–2011. Chest 2013;144:284-305
   PubMed Web of Science ®Google Scholar
• NIH/NHLBI. Morbidity & Mortality: 2004 Chart book on cardiovascular, lung, and blood diseases. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 2004
   Google Scholar
• NIH/NHLBI. Morbidity & Mortality: 2007 Chart book on cardiovascular, lung, and blood diseases. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 2007
   Google Scholar
• NIH/NHLBI. Morbidity & Mortality: 2009 Chart book on cardiovascular, lung, and blood diseases. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 2009
   Google Scholar
• Ford ES, Murphy LB, Khavjou O, et al. Total and state-specific medical and absenteeism costs of COPD among adults aged >/=18 years in the United States for 2010 and projections through 2020. Chest 2015;147:31-45
   PubMed Web of Science ®Google Scholar
• Nannini LJ, Poole P, Milan SJ, et al. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013:(11);Cd003794
   PubMed Web of Science ®Google Scholar
• Nannini LJ, Poole P, Milan SJ, et al. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013;(8):Cd006826
   PubMed Web of Science ®Google Scholar
• Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;(9):Cd006829
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Bailey W, Crater G, et al. Disease severity and symptoms among patients receiving monotherapy for COPD. Prim Care Respir J 2011;20:46-53
   PubMedGoogle Scholar
• Dalal AA, Patel J, D’Souza A, et al. Impact of COPD exacerbation frequency on costs for a managed care population. J Manag Care Spec Pharm 2015;21:575-83
   PubMed Web of Science ®Google Scholar
• Dalal AA, Shah M, D’Souza AO, et al. Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy. Respir Med 2012;106:829-37
   PubMed Web of Science ®Google Scholar
• Yu AP, Yang H, Wu EQ, et al. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ 2011;14:315-23
   PubMedGoogle Scholar
• Schermer T, van Weel C, Barten F, et al. Prevention and management of chronic obstructive pulmonary disease (COPD) in primary care: position paper of the European Forum for Primary Care. Qual Prim Care. 2008;16:363-77
   PubMedGoogle Scholar
• Akazawa M, Hayflinger DC, Stanford RH, et al. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease. Am J Manag Care 2008;14:438-48
   PubMed Web of Science ®Google Scholar
• Delea TE, Hagiwara M, Dalal AA, et al. Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies. Curr Med Res Opin 2009;25:1-13
   PubMed Web of Science ®Google Scholar
• Rascati KL, Stanford RH, Borker R. A comparison of the risk of hospitalizations due to chronicobstructive pulmonary disease in medicaid patients with various medication regimens, including ipratropium, inhaled corticosteroids, salmeterol, or their combination. Clin Ther 2005;27:346-54
   PubMed Web of Science ®Google Scholar
• Cheyne L, Irvin-Sellers MJ, White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015;(9):Cd009552
   PubMed Web of Science ®Google Scholar
• Oostenbrink JB, Rutten-van Molken MP, Al MJ, et al. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004;23:241-9
   PubMed Web of Science ®Google Scholar
• Dalal AA, Candrilli SD, Davis KL. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD. Manag Care 2011;20:46-50, 53–5
   PubMedGoogle Scholar
• Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26
   PubMed Web of Science ®Google Scholar
• Dalal AA, Petersen H, Simoni-Wastila L, et al. Healthcare costs associated with initial maintenance therapy with fluticasone propionate 250 mug/salmeterol 50 mug combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPD. J Med Econ 2009;12:339-47
   PubMedGoogle Scholar
• Halpern R, Baker CL, Su J, et al. Outcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary disease. Patient Prefer Adherence 2011;5:375-88
   PubMed Web of Science ®Google Scholar
• Roberts MH, Dalal AA. Clinical and economic outcomes in an observational study of COPD maintenance therapies: multivariable regression versus propensity score matching. Int J Chron Obstruct Pulmon Dis 2012;7:221-33
   PubMed Web of Science ®Google Scholar
• Dalal AA, Roberts MH, Petersen HV, et al. Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2010;6:13-22
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-83
   PubMedGoogle Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
   PubMed Web of Science ®Google Scholar
• Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993;46:1075-9; discussion 1081–90
   PubMed Web of Science ®Google Scholar
• D’Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol 1996;49:1429-33
   PubMed Web of Science ®Google Scholar
• Dalal AA, Shah MB, D’Souza AO, et al. Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD. Respir Res 2012;13:41
   PubMed Web of Science ®Google Scholar
• Kern DM, Williams SA, Tunceli O, et al. A US database study characterizing patients initiating a budesonide-formoterol combination versus tiotropium bromide as initial maintenance therapy for chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2014;9:775-83
   PubMed Web of Science ®Google Scholar
• Trudo F, Kern DM, Davis JR, et al. Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments. Int J Chron Obstruct Pulmon Dis 2015;10:2055-66
   PubMed Web of Science ®Google Scholar
• Kern DM, Davis J, Williams SA, et al. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study. Respir Res 2015;16:52
   PubMed Web of Science ®Google Scholar